Circular RNA delivered with lipid vehicles enables in vivo CAR expression, reducing lymphodepletion, procedure complexity, and toxic side effects.
A branched peptide carrier uses charged and hydrophobic segments to protect nucleic acids, improve cell uptake, and reduce cytotoxicity.
pH-responsive ionizable lipids stay less toxic in circulation and become cationic in endosomes to improve nucleic acid transfection.
An anionic methionine sulfoxide copolymer shields cationic gene carriers to reduce aggregation and immune response without sacrificing uptake.
Microencapsulated mRNA delivery of mesodermal factors enables 5-day cardiopoietic stem cell generation with lower cost and less protocol variability.
Lipid particles deliver antigen and costimulatory genes to tumor cells, restoring CAR-T recognition when antigen expression fades.
Hydrophobic oligonucleotide modification enables simple exosome incubation with over 80% loading efficiency and scalable therapeutic production.
A CuAAC-accelerating ligand enables live-cell biomolecule labeling at lower copper levels, improving biocompatibility and reaction sensitivity.
Lipid particles deliver CAR antigen and costimulatory genes to tumor cells, restoring recognition and sustaining CAR-T therapy over time.
Separate chambers keep cationic and polymer components stable until mixing, enabling easy formation of drug-loaded nanoparticles at use.
Liposome-encapsulated mRNAs encoding antibody chains enable systemic in vivo antibody production while avoiding DNA persistence risks.
Ranks guide sequences by on-target and off-target scores to build custom CRISPR libraries with focused gene coverage and fewer cells.